The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
Authors
Bates, Ruth L.Payne, Sarah J.
Drury, S.L.
Nelson, Paul N.
Isenberg, D.A.
Murphy, John J.
Frampton, Geoffrey
Issue Date
2003
Metadata
Show full item recordAbstract
We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.Citation
Lupus 2003, 12(8): 617-622Publisher
SAGE PublicationsPubMed ID
12945721Additional Links
http://direct.bl.uk/bld/PlaceOrder.do?UIN=136076849&ETOC=RN&from=searchenginehttp://lup.sagepub.com/cgi/content/abstract/12/8/617Type
Journal articleLanguage
enDescription
Metadata record onlyISSN
0961-2033ae974a485f413a2113503eed53cd6c53
10.1191/0961203303lu436oa